News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pro-Pharmaceuticals, Inc. (PRW) Meeting Scheduled With The FDA; April 11th Meeting To Discuss NDA Submission For Co-administration Of DAVANAT(R) With 5-FU To Treat Cancer Patients



2/23/2007 12:42:45 PM

NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (Amex: PRW), a developer of novel carbohydrate compounds, today announced that a meeting with the U.S. Food & Drug Administration (FDA) is scheduled for April 11th to discuss data and plans for submitting a New Drug Application (NDA), under Section 505(b)(2) for DAVANATĀ® to be co-administered with 5-Fluorouracil (5-FU) to treat cancer patients. 5-FU is one of the most widely used chemotherapy drugs in the world.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES